Opdivo vs Tagrisso
A side-by-side look at two oncology medications advertised on TV. Informational only — not medical advice.
Maintained by TVPills Editorial Team · Site updated November 4, 2026 (not a product-label review)
| Attribute | US Opdivo | US Tagrisso |
|---|---|---|
| Generic name | nivolumab Unverified catalogue summary (Generic name) for Opdivo in US; not checked against current local product information. | osimertinib Unverified catalogue summary (Generic name) for Tagrisso in US; not checked against current local product information. |
| Drug class | See official local label Unverified catalogue summary (Drug class) for Opdivo in US; not checked against current local product information. | See official local label Unverified catalogue summary (Drug class) for Tagrisso in US; not checked against current local product information. |
| Treats | Multiple cancers Unverified catalogue summary (Treats) for Opdivo in US; not checked against current local product information. | EGFR mutation-positive non-small cell lung cancer Unverified catalogue summary (Treats) for Tagrisso in US; not checked against current local product information. |
| Category | Oncology Unverified catalogue summary (Category) for Opdivo in US; not checked against current local product information. | Oncology Unverified catalogue summary (Category) for Tagrisso in US; not checked against current local product information. |
| Manufacturer | Bristol-Myers Squibb Unverified catalogue summary (Manufacturer) for Opdivo in US; not checked against current local product information. | AstraZeneca Unverified catalogue summary (Manufacturer) for Tagrisso in US; not checked against current local product information. |
| Year approved | — Unverified catalogue summary (Year approved) for Opdivo in US; not checked against current local product information. | — Unverified catalogue summary (Year approved) for Tagrisso in US; not checked against current local product information. |
| Catalogue warning level | Safety summary withheld — check official label Unverified catalogue summary (Catalogue warning level) for Opdivo in US; not checked against current local product information. | Safety summary withheld — check official label Unverified catalogue summary (Catalogue warning level) for Tagrisso in US; not checked against current local product information. |
| Est. TV ad spend | $150M | — |
| Side effects and serious risks | — Unverified catalogue summary (Side effects and serious risks) for Opdivo in US; not checked against current local product information. | — Unverified catalogue summary (Side effects and serious risks) for Tagrisso in US; not checked against current local product information. |
Sources and editorial standards
Use the current DailyMed labels to verify approved uses, boxed warnings, and side effects for each medication. Label results can differ by product, strength, and formulation.
Page updated November 4, 2026; the linked resources have not necessarily been reviewed on this date.
Frequently asked questions
Is Opdivo or Tagrisso better?
This directory does not compare clinical effectiveness or safety. Listing Opdivo and Tagrisso together does not establish shared approved indications, equivalence or suitability as substitutes. Consult the correct local labels and your prescriber.
What's the difference between Opdivo and Tagrisso?
The table shows catalogue identification and estimated advertising information for Opdivo and Tagrisso, not a verified medical comparison. Medical descriptions, mechanisms and safety summaries are withheld.
Which one spends more on TV ads?
Opdivo has the larger estimated TV advertising budget of the two.